SA court upholds Sanofi docetaxel patent and bans Cipla's cut-price product
This article was originally published in Scrip
Executive Summary
The Supreme Court of Appeal of South Africa has prohibited Cipla's partners from marketing a generic version of Sanofi's anticancer Taxotere (docetaxel) there pending the outcome of a trial to confirm Sanofi's patent rights until the South African patent on the product expires on 30 November 2013.